Fluconazole, serum or plasma
Fluconazole, serum or plasma-994
Fluconazole, serum or plasma
994
LAB994
MSO
Diflucan
Treatment of candidiasis, cryptococcal meningitis, and antifungal prophylaxis in allogeneic bone marrow transplant recipients.
Serum
1.0 mL
0.5 mL
- Allow sample to clot
- Spin within two (2) hours of sample collection
- Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum
EDTA plasma
Immediatley following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting
- Spin within two (2) hours of sample collection
- Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as EDTA plasma
Transfer vial/tube with cap - 12mL (LabCorp)
Refrigerated (preferred) - 14 days
Ambient - 14 days
Frozen - 14 days
- Serum from gel-barrier tubes is not acceptable and will be rejected
LabCorp Burlington (700485): R-NX
Mo - Fr
3 - 7 days
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
The average peak concentration in fasted patients one to two hours after administration of a single oral 400mg dose of Fluconazole was 6.72 µg/mL (range 4.12 - 8.08).
No relationship between plasma concentrations and efficacy or toxicity has been identified for Fluconazole, however, exposure may be altered in instances of renal dysfunction or renal replacement therapy.
80299
Result 10987-6
10/09/2019
10/14/2019
12/27/2023